Sir,

We thank Agilli *et al*.\[[@ref1]\] for commenting on our manuscript.\[[@ref2]\] We would like to respond to their concerns.

Agilli *et al*.\[[@ref1]\] suggested to use erythrocyte sedimentation rate (ESR) and complete blood count, in addition to C-reactive protein (CRP) to assess inflammatory status. Osei-Bimpong *et al*.\[[@ref3]\] suggested that ESR and CRP are equally useful and reliable tests for screening and showed that after 40 years of age, there is an age-related elevation of ESR, increasing steadily, especially after age 60 years. CRP is also affected by age, but to a much lesser extent.\[[@ref3]\] The mean age of our cholelithiasis group was 51 years and control group was 57 years, and it is clear that CRP reflects inflammatory status much better than ESR in this age group.\[[@ref3]\] In 1992, the combination of abdominal ultrasonography and measurement of CRP was recommended in the routine evaluation of all patients with suspected acute cholecystitis.\[[@ref4]\] In recent studies, elevated CRP has been found to have a high predictive value in predicting gangrenous cholecystitis\[[@ref5]\] and conversion from laparoscopic to open cholecystectomy.\[[@ref6]\] Agilli *et al*. refer to the study by Kono *et al*.\[[@ref7]\] to criticize our use of CRP. Kono *et al*. performed a study on 11 children and showed that some of the studied 3 months to 3-year-old children with bacterial infection did not mount an elevated CRP level in response to infection.\[[@ref7]\] Our study population of adults and those small children are quite different patient groups. Therefore, we believe that utilization of CRP level was enough to exclude both control and cholelithiasis subjects with signs of inflammation and the determination of the study and control groups was probably reliable.

The second issue raised by Agilli *et al*. is about methodology.\[[@ref1]\] They point to inaccuracy of thiobarbituric acid reactive substances (TBRAS) assay on measuring malondialdehyde (MDA) level and suggest using a chromatographic assay. TBRAS assay detects oxidized lipids, saturated and unsaturated aldehydes, sucrose, urea, and various chromogens in addition to MDA, causing overestimation of MDA.\[[@ref8]\] As subjects with renal and endocrine diseases were excluded from the study, we believe that the observed difference in TBARS assay reflects the difference in MDA levels and doubt that other chromogens and other TBARS caused the observed difference. In any case, we agree that a chromatographic assay is superior to TBARS assay. We suggest that further studies should employ a chromatographic assay in determining MDA.

The third issue is about the errors in tables. We thank Agilli *et al*. for pointing out several errors in [Table 1](#T1){ref-type="table"}. Those were corrected in the revised [table 1](#T1){ref-type="table"} presented with this communication. There was an error in the mean age of control subjects. The mean age of the controls was 56.93 years and was significantly higher than the mean age of the subjects with cholelithiasis (*P* = 0.016). There was an error in the calculation of low-density lipoprotein cholesterol (LDL-C) by the Friedewald formula in healthy controls. The correct calculation of LDL-C from the mean total cholesterol, the mean high-density lipoprotein cholesterol and the mean triglycerides is 100.86 mg/dL for the healthy control group. There was an error in the reported mean aspartate transaminase (AST) levels in both the control and the cholelithiasis groups. AST level of the healthy control group was 30.00 IU/L. AST level of the cholelithiasis group was 25.48 IU/L. The mean AST level of control subjects was significantly higher than the mean AST level of cholelithiasis subjects (*P* \< 0.001). The mean gamma-glutamyltransferase (GGT) level for control subjects was correct and was 41.70 IU/L, but the mean GGT level of cholelithiasis subjects was reported wrong and should have been 35.81 IU/L. The mean GGT level of control subjects was significantly higher than the mean GGT level of cholelithiasis subjects (*P* = 0.002). These corrections are shown in the revised [table 1](#T1){ref-type="table"} in this communication. The following corrections need to be done in the text of the manuscript that pertains to the revised [table 1](#T1){ref-type="table"}. In the Abstract, in the first sentence of the Patients and Methods section, there is an error in the number and age of subjects without cholelithiasis. The correct numbers are 25 women, 15 men, mean age 57 years, and SD 12 years. The second sentence of the Results section should be as follows: "Twenty-five women (62.5%) and 15 men (37.5%) with a mean age ± SD of 56.93 ± 11.73 years were included in the control group and control subjects were significantly older than cholelithiasis subjects (*P* = 0.016)." These errors were also present in [table 1](#T1){ref-type="table"} of another publication of ours that derived data from the same subject group.\[[@ref9]\] This should have been mentioned in the Acknowledgements as well as the editing and submission assistance by Ahmet Selçuk Can (the third author of this letter). Aytaç Atamer and Yıldız Atamer is responsible for the integrity of the published data.\[[@ref2]\] Ahmet Selçuk Can is responsible from editing and submission of the published manuscript\[[@ref2]\] and writing and submission of this letter. We agree with Agilli *et al*.\[[@ref1]\] and accept that several errors make the published study\[[@ref2]\] unreliable.
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The fourth issue is about the interpretation of our study results. Previous studies show that the metabolic syndrome is one of the risk factors for cholelithiasis.\[[@ref10][@ref11]\] We cannot differentiate from our data if lower paraoxonase activity and higher MDA levels we observed in cholelithiasis subjects compared with controls are due to cholelithiasis *per se* or the metabolic syndrome. Our study shows that subjects with cholelithiasis and with the components of the metabolic syndrome have evidence of more lipid peroxidation and less antioxidant capacity than subjects with cholelithiasis and without the components of the metabolic syndrome.\[[@ref2]\]
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